MRNA · Moderna, Inc.
10-Q filed 2026-07-31 period 2026-06-30
54 Caution
confidence High · source filing on SEC.gov ↗
- Net loss reached $2,125 million for the first six months of 2026, driven by high R&D expenses of $1,300 million and cost of sales of $1,048 million.
- Cash and cash equivalents decreased to $1,723 million from $2,595 million at the end of 2025, primarily due to negative operating cash flow of $1,156 million.
- Regulatory progress continued with the European Commission's approval of the mCOMBRIAX flu/COVID combination vaccine in April 2026.
vs. prior filing (10-Q filed 2026-05-01)
FHS 57 → 54 (-3) · Caution -> Caution
Profitability -5Balance sheet -10Cash generation -5Risk flags +10Mgmt signal -5
Filing Health Score pillars
Profitability 25%
25
According to the Condensed Consolidated Statements of Operations, total revenue increased to $534 million for the six months ended June 30, 2026, but the company recorded a net loss of $2,125 million due to high operating expenses.
Balance sheet 20%
75
As shown in the Condensed Consolidated Balance Sheets, cash and cash equivalents stood at $1,723 million and current investments at $3,415 million, comfortably exceeding long-term debt of $591 million, while outstanding shares rose to 399 million.
Cash generation 20%
30
The Condensed Consolidated Statements of Cash Flows show that net cash used in operating activities was $(1,156) million for the six months ended June 30, 2026, which combined with $99 million in capex resulted in negative free cash flow.
Risk flags 20%
90
Item 1A notes no material changes to the risk factors previously disclosed, and there are no going-concern doubts or restatements, though Item 5 details several new Rule 10b5-1 trading arrangements for key executives.
Mgmt signal 15%
60
Note 2 indicates that management anticipates seasonal fluctuations in demand for COVID and RSV vaccines, with higher sales expected during the fall and winter seasons, while Note 3 highlights the European approval of mCOMBRIAX.
Key metrics (Six Months Ended June 30, 2026)
period: Six Months Ended June 30, 2026
total debt: $591 million
cash and equivalents: $1,723 million
shares outstanding: 399 million
revenue: $534 million
net income: $(2,125) million
operating cash flow: $(1,156) million
Gemma triage notes (pre-analysis, second opinion)
None for this filing.Automated research summaries derived from SEC filings. Not investment advice.